 Home > Biochemistry News > Biotechnology News > More than 500 million US dollars help the development of specific cytokine therapy Merck & Co. reached a cooperation

More than 500 million US dollars help the development of specific cytokine therapy Merck & Co. reached a cooperation

 Last Update: 2021-11-14
 Source: Internet
 Author: User

Tags

single platform

sales development program

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 1, 2021, Synthekine announced that it has reached a global research cooperation and licensing agreement with Merck & Co.
(MSD)
.

The collaboration will use Synthekine's proprietary alternative cytokine agonist technology platform to discover, develop and commercialize new cytokine therapeutic drugs

According to the terms of the agreement, Synthekine and Merck will jointly take charge of the initial research work, and Merck will have the development, production and commercialization rights of alternative cytokine agonists for up to two cytokine targets
.

Synthekine will be eligible for development, regulatory and commercialization milestones of up to $525 million, as well as tiered royalties on net sales for each target, and Merck will also provide research funding for Synthekine

Synthekine focuses on immunological research, based on structural insights into cytokines, combined with a variety of engineering techniques to develop optimized therapies for cytokine targets, mainly for the treatment of cancer and autoimmune diseases
.

These new immunotherapies include modified cytokines, cytokine-enhanced cell therapies, and alternative cytokine agonists

Cytokines are small molecular proteins that allow immune cells to "communicate", and are the core of the body's response to diseases and maintaining immune homeostasis
.

However, the development of cytokines as therapeutic drugs is challenging because cytokines are pleiotropic, which means that they can induce a series of responses in different cell types, leading to reduced efficacy or dose-limiting toxicity

Reference materials:

[1] Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.